(Q36899314)

17 August 2017

1 reference

title

Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products (English)

1 reference

17 August 2017

1 reference

1 reference

Nicolette CA

1

1 reference

17 August 2017

Healey D

2

1 reference

17 August 2017

Tcherepanova I

3

1 reference

17 August 2017

Whelton P

4

1 reference

17 August 2017

Monesmith T

5

1 reference

17 August 2017

Coombs L

6

1 reference

17 August 2017

Finke LH

7

1 reference

17 August 2017

Whiteside T

8

1 reference

17 August 2017

Miesowicz F

9

1 reference

17 August 2017

language of work or name

English

0 references

publication date

21 June 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25 Suppl 2

1 reference

17 August 2017

page(s)

B47-60

1 reference

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

The first 1000 dendritic cell vaccinees.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Clinical applications of dendritic cell vaccination in the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cell biology and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic Cell-Based Immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

The dendritic cell system and its role in immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cell regulation of TH1-TH2 development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cells as vectors for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cells as antigen presenting cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

The role of CD4+ T cell responses in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

DNA-based immunization by in vivo transfection of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

An improved RNA amplification procedure results in increased yield of autologous RNA transfected dendritic cell-based vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Cancer immunotherapy with mRNA-transfected dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Optimizing the exogenous antigen loading of monocyte-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Innate immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

High-level IL-12 production by human dendritic cells requires two signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Ambient particulate matter directs nonclassic dendritic cell activation and a mixed TH1/TH2-like cytokine response by naive CD4+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Autologous apoptotic T cells interact with dendritic cells, but do not affect their surface phenotype or their ability to induce recall immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Validation of the COSTIM bioassay for dendritic cell potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

The role of IL-13 in the generation of dendritic cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.06.006

1 reference

17 August 2017

1 reference